Author/Authors :
Akrami, Majid Breast Diseases Research Center - Department of Surgical Oncology - Shiraz University of Medical Sciences, Shiraz, Iran , Nasrollahi, Hamid Radiation Oncology Department - Shiraz University of Medical Sciences, Shiraz, Iran , Vahabi, Mostafa Breast Diseases Research Center - Department of Surgical Oncology - Shiraz University of Medical Sciences, Shiraz, Iran , Hamedi, Hassan Radiation Oncology Department - Shiraz University of Medical Sciences, Shiraz, Iran , Tahmasebi, Sedigheh Breast Diseases Research Center - Department of Surgical Oncology - Shiraz University of Medical Sciences, Shiraz, Iran , Karbasi, Sareh Radiation Oncology Department - Shiraz University of Medical Sciences, Shiraz, Iran , Pashnesaz, Mehran Breast Diseases Research Center - Department of Surgical Oncology - Shiraz University of Medical Sciences, Shiraz, Iran , Zangouri, Vahid Breast Diseases Research Center - Department of Surgical Oncology - Shiraz University of Medical Sciences, Shiraz, Iran , Yasin Karami, Mohammad Breast Diseases Research Center - Department of Surgical Oncology - Shiraz University of Medical Sciences, Shiraz, Iran , Mosallaei, Ahmad Radiation Oncology Department - Shiraz University of Medical Sciences, Shiraz, Iran , Talei, Abdolrasoul Breast Diseases Research Center - Department of Surgical Oncology - Shiraz University of Medical Sciences, Shiraz, Iran
Abstract :
Background: Intraoperative radiation therapy (IORT) is the delivery of radiation at the time of surgery. Whereas the dose delivered
by external beam radiation therapy (EBRT) is limited by the tolerance of the surrounding normal tissues, IORT allows exclusion of a
part or all of the dose-limiting sensitive structures by operative mobilization and/or direct shielding of these structures. The aim of the
present study was to report the non-breast cancer patients' outcomes after receiving IORT in Shiraz, Iran.
Methods: In this retrospective study, all cases who had received IORT and had non-breast malignancies were selected. Diagnosis
was confirmed by biopsy. Additional imaging was done by sonography, magnetic resonance imaging (MRI) and computed
tomography (CT). IORT was applied by self-shielded, LIAC 6-12 MeV Sordina mobile linear accelerator. Typically, a single dose of
10-21 Gy was given for maximally resected tumors. The statistical analyses were carried out using SPSS (version 21).
Results: Twenty-six patients were treated with IORT alone or combined with EBRT. Different tumors were treated, including
colorectal adenocarcinoma (10 cases, 38.4 %), Soft Tissue Sarcomas (STS, 11 cases, 42.3 %), head and neck cancers (3 cases, 11.5 %),
one cervix malignancy case and one paravertebral fibromatosis case. Mean ± SD overall survival was 15±14.89 (0-38) and 34.3±15.72
(14-53) months for colorectal cancer and STS, respectively.
Conclusion: IORT is mostly useful for pelvic and abdominal malignancies where normal bowel limits the dose that can be delivered
with EBRT. However, the dose delivered in a single fraction with IORT is rarely sufficient for tumor control; therefore, IORT is
usually preceded or followed by additional EBRT which should be further evaluated preferably in prospective randomized trials.
